TKPHF News and Press, Takeda Pharmaceutical Co Ltd From 03/01/23

Summary My portfolio, built specifically for my retirement ~20+ years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Meta and Tesla helped fuel another market beat in 2023 for me in February even disregarding depositing my 2022 IRA co...

Summary BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022. ORLADEYO is successfully differentiating itself in a multi-billion dollar market and is on track to achieve blockbuster status in a ...

Summary Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article. In 2023, the company's investors should receive a dividend of $2.28 per share, up...

Summary Poseida Therapeutics, Inc. granted Takeda its worldwide license to gene-therapy technologies that included piggyBac, Cas-Clover, and biodegradable DNA/ RNA nanoparticle deliveries, including treatments for Hemophilia A. Poseida is advancing its broad pipeline with its CAR-T port...

Summary DexCom is young, innovative, admired, and (consequently) highly valued. Embecta is old, lethargic, lacks coverage, and (consequently) lowly valued. Growth and value investors may find respective equities interesting. I use DXCM and EMBC as a lens to view developments in ...

The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction with their 2023 Q3 earnings call. For further details see: Takeda Pharmaceutical Company Limited 2023 Q3 - Results - Earnings Call Presentation

Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Conference Call February 2, 2023 05:30 ET Company Participants Christopher O’Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer Andy Plump - President, R&D ...

Summary Albireo, Mirum Pharmaceuticals, Inc.'s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. The biggest value driver of Mirum is Livmarli, currently the only approved life-saving product in a rare pediatric disease market worth $500 mill...

Summary HutchMed out-licensed global rights (ex-China) for a colorectal cancer therapy, fruquintinib, to Takeda Pharmaceutical in a deal worth up to $1.13 billion, including $400 million upfront. Guangzhou Akeso was approved to market penpulimab, an anti PD-1 mAb, as a first-line treatm...

Summary Ascendis is a mid-cap commercial biotech based in Denmark. Currently, it trades around $6.7B market cap, and the company holds $900M cash. Skytrofa (TransCon hGh) is Ascendis' lead approved agent for pediatric growth hormone deficiency (GHD), where the commercial update was luke...